National Cancer Institute Initiates Studies on ImmuneRegen BioSciences' Vaccine Adjuvant Candidate
January 27 2010 - 8:00AM
Marketwired
ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR
Biosciences Holdings Inc. (OTCBB: IRBS), today announced the
execution of an agreement with the National Institute of Health
(NIH) / National Cancer Institute (NCI) to commence studies
utilizing ImmuneRegen's Homspera. Under the agreement, the NIH will
perform exploratory studies on Homspera relating to mucosal
immunity that might lead to subsequent evaluation in models of HIV
infection.
Recent studies have found Homspera to be effective in enhancing
the efficacy of a novel cancer vaccine, and previous studies have
revealed efficacy in the space of infectious disease vaccines,
specifically influenza. The studies to be performed at NIH/NCI are
designed to expand on that research and further define the
mechanisms that make Homspera an effective vaccine adjuvant.
The research will be directed by Jay A. Berzofsky, M.D., Ph.D.,
Chief of the Vaccine Branch at the Center for Cancer Research
within the National Cancer Institute. Dr. Berzofsky has published
over 435 scientific publications and has received a number of
awards, including the U.S. Public Health Service Superior Service
Award. He is the past President of the American Society for
Clinical Investigation, and a Fellow of the American Association
for the Advancement of Science, and was elected Distinguished
Alumnus of the Year for 2007 by the Albert Einstein College of
Medicine. He was also elected Chair of the Medical Sciences Section
of the American Association for the Advancement of Science (AAAS)
2007-08. He most recently won the NIH Director's Award and NCI
Merit Award in 2008.
"We are pleased that Dr. Berzofsky and his team are interested
in evaluating the impact of Homspera on mucosal immunity, and hope
this is the beginning of a relationship that takes our compound
into a number of potential vaccine adjuvant studies," said Hal
Siegel, Ph.D., ImmuneRegen's Chief Scientific Officer.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences Inc., a wholly owned subsidiary of IR
BioSciences Holdings, Inc. (OTCBB: IRBS), is a development-stage
biotechnology company focused on the research, development and
licensing of Homspera®. Homspera is an adult stem cell active
compound that in study results has been shown to regenerate and
strengthen the immune system and enhance wound healing. Homspera is
being developed for potential use against infectious diseases as a
stand-alone or combination therapy and as a vaccine adjuvant. To
advance its mission, the Scottsdale, Arizona based company has
forged numerous study partnerships with industry and academic
leaders, including Celgene Cellular Therapeutics, HemoGenix,
Lovelace Respiratory Research Institute and Virion Systems. For
more information, please visit www.immuneregen.com.
Statements about the Company's future expectations, including
statements about the potential use and scientific results for the
Company's drug candidates, science and technology, and all other
statements in this press release other than historical facts, are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created
thereby. These future events may not occur as and when expected, if
at all, and, together with the Company's business, are subject to
various risks and uncertainties. The Company's actual results could
differ materially from expected results as a result of a number of
factors, including the uncertainties inherent in research and
development collaborations, pre-clinical and clinical trials and
product development programs (including, but not limited to the
fact that future results or research and development efforts may
prove less encouraging than current results or cause side effects
not observed in current pre-clinical trials), the evaluation of
potential opportunities, the level of corporate expenditures and
monies available for further studies, capital market conditions,
and others set forth in the Company's periodic report on Form 10-Q
for the three months ended September 30, 2009 as filed with the
Securities and Exchange Commission and report on Form 10-K for the
year ended December 31, 2008 as filed with the Securities and
Exchange Commission. There are no guarantees that any of the
Company's proposed products will prove to be commercially
successful. The Company undertakes no duty to update
forward-looking statements.
Contact: Michael K. Wilhelm ImmuneRegen BioSciences Inc. Phone:
480-922-3926 Email: Email Contact John Fermanis ImmuneRegen
BioSciences Inc. Phone: 480-922-3926 Email: Email Contact
IR BioSciences (CE) (USOTC:IRBS)
Historical Stock Chart
From May 2024 to Jun 2024
IR BioSciences (CE) (USOTC:IRBS)
Historical Stock Chart
From Jun 2023 to Jun 2024